Journal
EXPERIMENTAL DERMATOLOGY
Volume 23, Issue 7, Pages 471-472Publisher
WILEY-BLACKWELL
DOI: 10.1111/exd.12400
Keywords
BH3-mimetic; drug resistance; intrinsic apoptosis pathway; melanoma therapy; SMAC-mimetic
Categories
Funding
- Cancer Council NSW [RG 09-08, RG 13-06]
- Cancer Australia/Cure Cancer Australia Foundation [570778]
- Cancer Institute New South Wales [08/RFG/1-27]
- National Health and Medical Research Council Australia [1003637]
Ask authors/readers for more resources
Drug resistance in melanoma is commonly attributed to ineffective apoptotic pathways. Targeting apoptosis regulators is thus considered a promising approach to sensitizing melanoma to therapy. In the previous issue of Experimental Dermatology, Plotz and Eberle discuss the role that apoptosis plays in melanoma progression and drug resistance and the utility of apoptosis-inducing BH3-mimetics as targeted therapy. There are a number of compounds in clinical development and the field seems close to translating recent findings into benefits for patients with melanoma. Thus, this viewpoint is timely and achieves a valuable summary of the current state of apoptosis-inducing therapy of melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available